ImmuCell
ICCC
21 hedge funds and large institutions have $6.29M invested in ImmuCell in 2016 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
170% more capital invested
Capital invested by funds: $2.33M → $6.29M (+$3.96M)
40% more funds holding
Funds holding: 15 → 21 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$1.7M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.35M |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$551K |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$287K |
| 5 |
Morgan Stanley
New York
|
+$91.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$144K |
ICCC Hedge Fund Activity: Q1 2016 in Review
21 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in ImmuCell (ICCC) for Q1 2016, worth a combined $6.29M — up 170% from $2.33M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ICCC positions and 1 closed out — a net gain of 6 holders — while 8 added to existing stakes and 0 trimmed.
The largest buyer was Northpointe Capital, opening a new position worth an estimated $1.7M. The largest seller was Shepherd Kaplan Krochuk, exiting entirely with an estimated $144K sold.
- 21 institutional investors held ImmuCell (ICCC) as of Q1 2016, up from 15 in Q4 2015.
- Funds reported $6.29M of ImmuCell stock for Q1 2016, up 170% quarter-over-quarter.
- 7 funds opened new ImmuCell positions in Q1 2016 and 1 closed out, a net change of +6 holders.
- The largest ImmuCell buyer in Q1 2016 was Northpointe Capital, an estimated $1.7M added.
- The largest ImmuCell seller in Q1 2016 was Shepherd Kaplan Krochuk, an estimated $144K sold.
Based on aggregated 13F filings for Q1 2016.